CD20 is a cell surface tetraspan receptor expressed exclusively on B-lymphocytes, which are differentiated from pluripotent stem cells in the bone marrow and develop through the pro-B, pre-B, immature B and mature B stages. In addition to being expressed in normal B cells, CD20 is also expressed in tumor cells of B-cell origin, such as lymphomas and leukaemias.

Currently, U.S. Food and Drug Administration (FDA) has approved 27 antibody drugs targeting CD20 in the world, and there are 93 biologics targeting CD20 in the clinical stage of development. Of these clinical projects, there are 22 CART-T gene therapies and 71 antibody drugs. Moreover, antibodies and gene therapy targeting CD20 have also made great progress in treating the disease. Read more>>

CUSABIO is committed to developing drug target proteins for several years. The CD20 protein (CSB-MP015007HU) from CUSABIO is expressed in the mammalian cell with activity and structure validation.

Part of Validation Data

The specificity of CD20 protein validated by Western Blot CSB-MP015007HU is detected by Mouse anti-6*His monoclonal antibody.

The bioactivity of CD20 validated by Functional ELISA Immobilized human CD20 at 2 μg/ml can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC50 is 3.243-7.085 ng/mL.

The structure of CD20 validated by TEM The presence of VLP-like structures was confirmed by TEM.

All products of CD20>>.

If you can't find the protein you desired, you can contact us to customize.